<p>CI = Confidence interval, TP = True positive, FP = False positive, FN = False negative, Colpo. = colposcopic biopsy</p><p>*All costs are presented with a range of 25% higher and lower.</p><p>**Considers the colposcopic biopsy costs for true positives plus false positives. Not clinically relevant for VIA.</p><p>***For initial screen plus colposcopic biopsy when indicated. Excludes colposcopic biopsy for VIA because not clinically relevant.</p><p>Screening outcomes, costs for screening analytic cohort for CIN 2+ (Functional Limit scenario).</p
<p><i>Screen detected</i> indicates proportion of cases of CIN2+ detected by hc2, and <i>screen unde...
<p>The strategy with maximum net monetary benefit is depicted as a function of the assumed efficacy ...
Colorectal cancer (CRC) fulfills the World Health Organization criteria for mass screening, but scre...
<p>ICER = Incremental cost-effectiveness ratio, colpo. = colposcopic biopsy</p><p>*For initial scree...
<p>* Note that this method is not currently allowed under existing guidelines, but was presented as ...
Histological outcomes and number of colposcopies performed per CIN2+/CIN3+ case detected in the inte...
§<p>94.4% (878/930) of women with abnormal Pap smear/VIA and 25% (63/272) women with negative VIA/Pa...
<p>NB: The line represents the cost-effectiveness threshold, or frontier. All interventions or combi...
<p>Colpo. = colposcopic biopsy, LSIL = low grade squamous intraepithelial lesions, ASCUS = atypical ...
Objective: To define the relationship between the number of cervical colposcopic biopsies performed ...
Background: Colposcopic evaluation and guided biopsy is an important diagnostic step and standard of...
Objective To estimate the cost effectiveness of alternative methods of managing low grade cervical c...
Objective: To devise an optimal cytology threshold for colposcopy referral in resource-limited setti...
OBJECTIVES: To evaluate the direct costs of first and repeat colorectal cancer screening by immuno...
Cancer of the colon and rectum is a major cause of ill-health. Options for reducing the burden of th...
<p><i>Screen detected</i> indicates proportion of cases of CIN2+ detected by hc2, and <i>screen unde...
<p>The strategy with maximum net monetary benefit is depicted as a function of the assumed efficacy ...
Colorectal cancer (CRC) fulfills the World Health Organization criteria for mass screening, but scre...
<p>ICER = Incremental cost-effectiveness ratio, colpo. = colposcopic biopsy</p><p>*For initial scree...
<p>* Note that this method is not currently allowed under existing guidelines, but was presented as ...
Histological outcomes and number of colposcopies performed per CIN2+/CIN3+ case detected in the inte...
§<p>94.4% (878/930) of women with abnormal Pap smear/VIA and 25% (63/272) women with negative VIA/Pa...
<p>NB: The line represents the cost-effectiveness threshold, or frontier. All interventions or combi...
<p>Colpo. = colposcopic biopsy, LSIL = low grade squamous intraepithelial lesions, ASCUS = atypical ...
Objective: To define the relationship between the number of cervical colposcopic biopsies performed ...
Background: Colposcopic evaluation and guided biopsy is an important diagnostic step and standard of...
Objective To estimate the cost effectiveness of alternative methods of managing low grade cervical c...
Objective: To devise an optimal cytology threshold for colposcopy referral in resource-limited setti...
OBJECTIVES: To evaluate the direct costs of first and repeat colorectal cancer screening by immuno...
Cancer of the colon and rectum is a major cause of ill-health. Options for reducing the burden of th...
<p><i>Screen detected</i> indicates proportion of cases of CIN2+ detected by hc2, and <i>screen unde...
<p>The strategy with maximum net monetary benefit is depicted as a function of the assumed efficacy ...
Colorectal cancer (CRC) fulfills the World Health Organization criteria for mass screening, but scre...